- Report
- September 2025
- 362 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- July 2025
- 150 Pages
Global
From €3362EUR$3,850USD£2,921GBP
€4236EUR$4,850USD£3,680GBP
- Report
- March 2025
- 200 Pages
Global
From €2175EUR$2,490USD£1,889GBP
- Report
- August 2025
- 193 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 197 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 184 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- October 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- October 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- September 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- April 2025
- 200 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- March 2025
- 200 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- August 2025
- 190 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Drug Pipelines
- April 2025
- 240 Pages
Global
From €2620EUR$3,000USD£2,276GBP
- Clinical Trials
- April 2025
- 40 Pages
Global
From €1092EUR$1,250USD£948GBP
- Report
- June 2025
- 138 Pages
Global
From €2760EUR$3,160USD£2,397GBP
€3450EUR$3,950USD£2,997GBP
- Report
- June 2025
- 400 Pages
Global
From €4322EUR$4,949USD£3,755GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2436EUR$2,789USD£2,116GBP
- Report
- June 2025
- 109 Pages
Global
From €3013EUR$3,450USD£2,617GBP
- Report
- June 2025
- 198 Pages
Global
From €4323EUR$4,950USD£3,755GBP
- Report
- June 2025
- 97 Pages
Asia Pacific
From €3450EUR$3,950USD£2,997GBP

Sulfonylureas are a class of drugs used to treat type 2 diabetes. They work by stimulating the pancreas to produce more insulin, which helps the body to better process glucose. They are usually taken orally, and are often used in combination with other diabetes medications. Sulfonylureas are generally well-tolerated, but can cause side effects such as hypoglycemia, weight gain, and gastrointestinal upset.
The sulfonylureas market is a subset of the larger diabetes drugs market. It is a competitive market, with a range of products available from different manufacturers. The market is expected to grow in the coming years, driven by increasing prevalence of diabetes and the development of new drugs.
Some of the major companies in the sulfonylureas market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less Read more